We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Renalytix Plc | LSE:RENX | London | Ordinary Share | GB00BYWL4Y04 | ORD 0.25P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.00 | -3.77% | 25.50 | 25.00 | 26.00 | 26.50 | 25.50 | 26.50 | 43,867 | 14:00:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Services, Nec | 3.4M | -46.22M | -0.4626 | -0.55 | 25.48M |
From Apr 2019 to Apr 2024
TIDMEKF TIDMRENX
RNS Number : 5458G
EKF Diagnostics Holdings PLC
26 November 2020
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Sale of shares in Renalytix AI plc
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has sold 1,675,000 ordinary shares in Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) at a price of GBP4.60 per ordinary share, in response to strong institutional demand. The sale has resulted in gross proceeds of GBP7.705m to EKF and generated a profit of over GBP5.6m after dealing expenses.
Following this transaction EKF will continue to hold 1,002,981 ordinary shares in Renalytix AI plc.
Hot Features
Premium
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-executive Chairman Tel: +44 (0) 29 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer Tel: 020 7496 3000
Aubrey Powell / George Tzimas (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0) 7980 541 893 / +44 (0) 7584
391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCFELLLBFLLFBD
(END) Dow Jones Newswires
November 26, 2020 02:00 ET (07:00 GMT)
1 Year Renalytix Chart |
1 Month Renalytix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
